Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets.
Activating mutations, gene amplification and overexpression of human epidermal growth factor receptor (erbB or HER) family kinases have been implicated as integral contributors to a variety of cancers. However, there is increasing evidence that the HER family receptors propagate not only signals initiated by their own ligands but also those initiated by multiple other signaling pathways. Attenuation of HER family signaling is a developing strategy for the management of human malignancies and is the subject of a number of ongoing clinical trials. The purpose of this review is to provide a timely update of recent reports in the rapidly evolving area of HER family biology and the emerging integral role of these receptors in malignant transformation and as targets of cancer therapy.
Barnes
Christopher J
CJ
Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Kumar
Rakesh
R
D066246:ErbB Receptors / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000378:metabolism* / Q000628:therapy; D011960:Receptors, Estrogen; D015398:Signal Transduction; D015533:Transcriptional Activation; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D011960:Receptors, Estrogen; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors